bcl-2 protects against Fas-based but not perforin-based T cell-mediated cytolysis

International Immunology

Volumn 8, Issue 7, 1996, Pages 991-1000

  Lee, Richard K ^a   Spielman, Julie ^a   Podack, Eckhard R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

CD8; Cytotoxicity; Fas ligand; gld; T lymphocyte

Indexed keywords

FAS ANTIGEN; LIGAND; PERFORIN; PROTEIN BCL 2;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL MEDIATED CYTOTOXICITY; CELL MEMBRANE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; GENETIC TRANSFECTION; MEMBRANE DAMAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD95; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; MAST CELLS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; PORE FORMING CYTOTOXIC PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0030037138     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/8.7.991     Document Type: Article

References (80)

1. Kagi, D., Vignaux, F., Ledermann, B., Burki, K., Depraetere, V., Nagata, S., Hengartner, H. and Golstein, P. 1994. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528.
2. Lowin, B., Hahne, M., Mattmann, C. and Tschopp, J. 1994. Cytolytic T-cell cytotoxicily is mediated through perforin and fas lytic pathways. Nature 370:650.
3. Kojima, H., Shinohara, N., Hanaoka, S., Someya-Shirota. Y., Takagaki Y. Ohno, H., Saito, T., Katayama, T., Yagita, H., Okumura, K., Shinkai, Y., Alt, F. W., Matsuzawa, A., Yonehara, S. and Takayama, H. 1994. Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity 1:357.
4. Podack, E. R. and Tschopp, J. 1982. Polymerization of the ninth component of complement (C9): formation of poly (C9) with a tubular ultrastructure resembling the membrane attack complex of complement. Proc. Natl Acad. Sci. USA 79:574.
5. Lichtenheld, M. G., Olsen, K. J., Lu, P., Lowrey, D. M., Hameed, A., Hengartner, H. and Podack, E. R. 1988. Structure and function of human perforin. Nature 335:448.
6. Shinkai, Y., Takio, K. and Okumura, K. 1988. Homology of perforin to the ninth component of complement (C9). Nature 334:525.
7. Podack, E. R., Hengartner, H. and Lichtenheld, M. G. 1991. A central role of perforin in cytolysis? Annu. Rev. Immunol. 9:129.
8. Henkart, P. A. 1994. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity 1:343.
9. Apasov, S., Redegeld, F. and Sitkovsky, M. 1993. Cell-mediated cytotoxicity: contact and secreted factors. Curr. Opin. Immunol. 5:404.
10. Heusel, J. W., Wesselschmidt, R. L., Shresta, S., Russell, J. H. and Ley, T. J. 1994. Cytotoxic lymphocytes require granzyme B for the rapid induction of DMA fragmentation and apoptosis in allogeneic target cells. Cell 76:977.
11. Nakajima, H. and Henkart, P. A. 1994. Cytotoxic lymphocyte granzymes trigger a target cell internal disintegration pathway leading to cytolysis and DNA breakdown. J. Immunol. 152:1057.
12. cdc2 activation required for apoptosis. Science 263:1143.
13. Anel, A., Buferne, M., Boyer, C., Schmitt, V. A. and Golstein, P 1994. T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A. Eur. J. Immunol. 24:2469.
14. Vignaux, F., Vivier, E., Ma issen, B., Depratere, V., Nagata, S. and Golstein, P 1995. TCR/CD3 coupling to fas-based cytotoxicity. J. Exp. Med. 181-781.
15. Hanabuchi, S., Koyanagi, M., Kawasaki, A., Shinohara, N., Matsuzawa, A., Nishimura, Y., Kobayashi, Y., Yonehara, S., Yagita, H. and Okumura, K. 1994. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc. Natl Acad. Sci. USA 91:4930.
16. Suda, T., Takahashi, T., Golstein, P. and Nagata, S. 1993. Molecular cloning and expression of the fas ligand. a novel member of the tumor necrosis factor family. Cell 75:1169.
17. Rouvier, E., Luciani, M. F. and Golstein, P. 1993. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity J. Exp. Med. 177:195.
18. Yonehara, S., Ishii, A. and Yonehara, M. 1989. A cell-killing monoclonal antibody (anti-fas) to a cell surface antigen codownregulated with the receptor of tumor necrosis factor. J. Exp. Med. 169:1747.
19. Trauth, B. C., Klas, C., Peters, A. M., Matzku, S., Moller, P., Falk, W., Debatin, K.-M. and Krammer, P. H. 1989. Monoclonal antibodymediated tumor regression by Induction of apoptosis. Science 245:301.
20. Klas, C., Debatin, K. M., Jonker, R. R. and Krammer, P. H. 1993. Activation interferes with the APO-1 pathway in mature human T cells. Int. Immunol. 5:625.
21. + thymocytes by the anti-fas antibody. J. Exp. Med. 181:485.
22. Iwai, K., Miyawaki, T., Takizawa, T., Konno, A., Ohta, K., Yachie, A., Seki, H. and Taniguchi, N. 1994. Differential expression of bcl-2 and susceptibility to anti-fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Stood 84:1201.
23. Alderson, M. R., Armitage, R. J., Maraskovsky, E., Tough, T. W., Roux, E., Schooley, K., Ramsdell, F. and Lynch, D. H. 1993. Fas transduces activation signals in normal human T lymphocytes. J. Exp. Med 178:2231.
24. Mapara, M. Y., Bargou, R., Zugck, C., Dohner, H., Ustaoglu, F., Jonker, R. R., Krammer, P. H. and Dorken, B. 1993. APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur. J. Immunol. 23:702.
25. Miyawaki, T., Uehara, T., Nibu. R., Tsuji, T., Yachie, A., Yonehara, S. and Taniguchi, N. 1992. Differential expression of apoptosisrelated fas antigen on lymphocyte subpopulations in human peripheral blood. J. Immunol. 149:3753.
26. Watanabe, F. R., Brannan,C. I., Copeland, N. G., Jenkins, N. A. and Nagata, S. 1992. Lymphoproliferation disorder in mice explained by defects in fas antigen that mediates apoptosis. Nature 356:314.
27. Takahashi, T., Tanaka, M., Brannan, C. I., Jenkins, N. A., Copeland, N. G., Suda, T. and Nagata, S. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand. Cell 76:969.
28. Ramsdell, F., Seaman, M. S., Miller, R. E., Tough, T. W., Alderson, M. R. and Lynch, D. H. 1994. gldlgld mice are unable to express a functional ligand for fas. Eur. J. Immunol. 24:928.
29. Nunez, G. and Clarke, M. F. 1994. The bcl-2 family of proteins: regulators of cell death and survival Trends Cell Biol. 4:399.
30. Oltvai, Z. N., Milliman, C. L and Korsmeyer, S. J. 1993 Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609.
31. Vaux, D. L., Aguila, H. L. and Weissman, I. L. 1992. Bcl-2 prevents death of factor-deprived cells but fails to prevent apoptosis in targets of cell mediated killing. Int. Immunol. 4:821.
32. Reed, J. C. 1994. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 124:1.
33. Deng, G. and Podack, E. R. 1993. Suppression of apoptosis in a cytotoxic T-cell line by interleukin 2-mediated gene transcription and deregulated expression of the protooncogene bcl-2. Proc Natl Acad. Sci. USA 90:2189.
34. Zhong, L. T., Sarafian, T., Kane, D. J., Charles, A. C., Man, S. P., Edwards, R. H. and Bredesen, D. E. 1993. Bcl-2 inhibits death of central neural cells induced by multiple agents Proc. Natl Acad Sci. USA 90:4533.
35. Chiou, S. K., Rao, L. and White, E. 1994. Bcl-2 blocks p53-dependent apoptosis. Mol. Cell Biol. 14:2556
36. Strasser, A., Harris, A. W., Jacks, T. and Cory, S 1994. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79:329.
37. Bissonnette, R. P., Echeverri, F., Mahboubi, A. and Green, D. R 1992. Apoptotic cell death induced by c-myc is inhibited by bel-2. Nature 359:552.
38. Fanidi, A., Harrington, E. A. and Evan, G. I. 1992. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359:554.
39. Torigoe, T., Millan, J. A., Takayama, S., Taichman, R., Miyashita, T. and Reed, J. C. 1994. Bcl-2 inhibits T-cell-mediated cytolysis of a leukemia cell line. Cancer Res. 54:4851.
40. Strasser, A., Whittingham, S., Vaux, D. L., Bath, M. L., Adams, J M., Cory, S. and Harris, A. W. 1991. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc. Natl Acad. Sci. USA 88:8661.
41. Chiu, V. K., Walsh, C. M., Liu, C.-C., Reed, J. C. and Clark, W. R. 1995. Bcl-2 blocks degranulation but not fas-based cell-mediated cytotoxicity J. Immunol. 154:2023.
42. Itoh, N., Tsujimoto, Y. and Nagata, S. 1993. Effect of bcl-2 on fas antigen-mediated cell death J. Immunol. 151:621
43. Yoshino, T., Kondo, E., Cao, L., Takahashi, K., Hayashi, K., Nomura, S. and Akagi, T. 1994. Inverse expression of bcl-2 protein and fas antigen in lymphoblasts in peripheral lymph nodes and activated peripheral blood T and B lymphocytes. Stood 83:1856.
44. Salmon, M., Pilling, D., Borthwick, N. J., viner. N., Janossy, G., Bacon, P. A. and Akbar, A. N. 1994. The progressive differentiation of primed T cells is associated with an increasing susceptibility to apoptosis. Eur. J. Immunol. 24:892.
45. Owen-Schaub, L. B., Radinsky, R., Kruzel, E., Berry, K. and Yonehara, S. 1994. Anti-fas on nonhematopoietic tumors: levels of fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res. 54:1580.
46. Tanaka, M., Suda, T., Takahashi, T. and Nagata, S 1995. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 14:1129.
47. Kagi, D., Ledermann, B., Burki, K., Seiler, P., Odermatt, B., Olsen, K. J., Podack, E. R., Zinkernagel, R. M. and Hengartner, H. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31.
48. Karasuyama, H. and Melchers, F. 1988. Establishment of mouse cell lines which constitutively secrete large quantities of interleukins 2, 3, 4, or 5, using modified cDNA expression vectors. Eur J. Immunol. 18:97.
49. Linsley, P. S., Brady, W., Urnes, M., Grosmaire. L. S., Damle, N. K. and Ledbetter, J. A. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med, 174:561.
50. Hartman, S. C. and Mulligan, R. C. 1988. Two dominant-acting selectable markers for gene transfer studies in mammalian cells. Proc. Natl Acad. Sci. USA. 85:8047.
51. Podack, E. R. and Konisgsberg, P. J. 1984. Cytolytic T-cell granules: isolation, structural, biochemical and functional characterization. J. Exp. Med. 160:695.
52. Pasternak, M. S. and Eisen, H. N. 1985. A novel serine esterase expressed by cytotoxic T lymphocytes. Nature 314:743.
53. Walsh, C. M., Matloubian, M., Liu, C. C., Ueda. R., Kurahara, C. G., Christensen, J. L., Huang, M. T., Young, J. D., Ahmed, R. and Clark, W. R. 1994. Immune function in mice lacking the perforin gene Proc. Natl Acad Sci. USA. 91:10854.
54. Shi, L., Kam, C. M., Powers, J. C., Aebersold, R and Greenberg. A. H. 1992. Purification of three cytotoxic lymphocyte granule serine proteases that induce apoptosis through distinct substrate and target cell interactions. J. Exp. Med. 176:1521.
55. Shiver, J. W., Su, L. and Henkart, P. A. 1992. Cytotoxicity with target DNA breakdown by rat basophilic leukemia cells expressing both cytolysin and granzyme A. Cell 71:315.
56. Itoh, N. and Nagata, S. 1993. A novel protein domain required for apoptosis. Mutational analysis of human fas antigen. J. Biol. Chem. 268:10932.
57. Beutler, B. and van Huffel, C. 1994. Unraveling function in the TNF ligand and receptor families. Science 264:667.
58. Smith, C. A., Farrah, T. and Goodwin, R. G. 1994. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76:959.
59. Darmon, A. J., Nicholson, D. W. and Bleackley, R. C. 1995. Activation of the apoptotic protease CPP32 by cytotoxic T-cellderived granzyme B. Nature 377:446.
60. Dhein, J., Daniel, P. T., Trauth, B. C., Oehm, A., Moller, P and Krammer, P. H. 1992. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on crosslinking of APO-1 cell surface antigens. J. Immunol. 149:3166.
61. Daniel, P. T. and Krammer, P. H. 1994. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J. Immunol. 152:5624.
62. Cascino. I., Papoff, G., De Maria, R., Testi, R. and Ruberti, G. 1996. Fas/Apo-1(CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from fas-mediated apoptosis. J. Immunol. 156:13.
63. Boise, L. H., Gonzalez, G. M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nunez, G. and Thompson, C. B. 1993. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597.
64. Gottschalk, A. R., Boise, L. H., Thompson, C. B. and Quintans. J. 1994. Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. Proc. Natl Acad. Sci. USA. 91:7350.
65. Takayama, S., Sato, T., Krajewski, S., Kochel, K., Irie, S., Millan, J. A. and Reed, J. C. 1995. Cloning and functional analysis of BAG-1 : a novel bcl-2-binding protein with anti-cell death activity, Cell 80:279.
66. Boise, L. H., Minn, A. J., Noel, P. J., June, C. H., Accavitti. M. A., Lindsten, T. and Thompson, C. B. 1995. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xi. Immunity 3:87.
67. L and bcl-2, displaces bax and promotes cell death. Cell 80:285.
68. Eischen, C. M., Dick, C. J. and Leibson, P. J. 1994. Tyrosine kinase activation provides an early and requisite signal for fasinduced apoptosis. J Immunol 153:1947
69. Cifone, M. G., De, M. R., Roncaioli, P., Rippo, M. R., Azuma, M., Lanier, L. L., Santoni, A. and Testi, R. 1994. Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase J. Exp. Med 180:1547.
70. Kuida, K., Lippke, J. A., Ku, G., Harding, M. W., Livingston, D. J., Su, M. S.-S. and Flavell, R. A. 1995 Altered cytokine export and apoptosis in mice deficient in interleukin-1B converting enzyme Nature 267:2000.
71. Miura, M., Zhu, H., Rotello, R., Hartwieg, E. A. and Yuan, J. 1993. Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the C elegans cell death gene ced-3. Cell. 75:653.
72. Cheng, J., Zhou, T., Liu, C., Shapiro, J. P., Brauer, M. J., Kiefer, M. C., Barr, P. J. and Mountz, J. D. 1994. Protection from fasmediated apoptosis by a soluble form of the fas molecule. Science 263:1759.
73. Ohsako, S., Hara, M., Harigai, M., Fukasawa, C. and Kashiwazaki, S. 1994. Expression and function of fas antigen and bcl-2 in human systemic lupus erythematosus lymphocytes. Clin. Immunol. Immunopathol. 73:109
74. McDonnell, T J., Deane, N., Platt, F. M., Nunez, G., Jaeger, U., McKearn, J. P. and Korsmeyer, S. J. 1989 Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lympoproliferation. Cell 57:79.
75. Cohen, P. L. and Eisenberg, R. A. 1991. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev Immunol. 9:243.
76. Vignaux, F. and Golstein, P. 1994. Fas-based lymphocytemediated cytotoxicity against syngeneic activated lymphocytes a regulatory pathway? Eur. J. Immunol. 24:923.
77. Alderson, M. R., Tough, T. W., Davis-Smith, T., Braddy, S., Falk, B., Schooley, K. A., Goodwin, R. G., Smith, C. A., Ramsdell, F. and Lynch, D. H. 1995. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 181:71.
78. Brunner, T., Mogil, R. J., Laface, D., Yoo, N. J., Mahboubi, A., Echeverri, F., Martin, S. J., Force, W. R., Lynch, D. H., Ware. C. F. and Green, D. R. 1995. Cell-autonomous fas (CD95)/ fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373:441.
79. Dhein, J., Walczak, H., Baumler, C., Debatin, K.-M. and Krammer, P. H. 1995. Autocrine T-cell suicide mediated by APO-1/(Fas/ CD95). Nature 373:438.
80. Ju, S.-T, Panka, D. J., Cui, H., Ettinger, R., El-Khatib, M., Sherr, D. H., Stanger, B. Z. and Marshak-Rothstein, A. 1995. Fas (CD95)/ fas ligand interactions required for programmed cell death after T-cell activation. Nature 373:444.